Download Jul - Indian Pharmaceutical Association

The Indian Pharmaceutical Association
PHARMA PROFESSIONAL
Vol. 64




With the growth rate of 14 percent per year, the Indian pharmaceutical industry is well established for
rapid expansion. Indian
Pharmaceutical
Industry has made phenomenal progress over the years and made
Inside
the Issue
its impact in the global market. It has been recognized as a reliable source for drugs and drug
intermediates and pharmaceutical formulations. With the strengthening of the IPR scenario in the
quarter ended
31, 2005ofwitnessed
major in
changes in the Indian pharmaceutical
Incountry,
Focus:theInnovatives
andDecember
Recent Trends
CT Scanner
industry
like
the
foreign
MNCs
increasing
their
presence
in
India
through
expansions and collaborations;
Market
Indian companies competing with them through new product launches and gaining more number of
News
Briefapprovals. Many multinational companies have penetrated into India with an objective to
regulatory
marketing drugs and conducting clinical trials. Thus, Indian pharmaceutical research, manufacturing and
Product
Focus – Exelon
outsourcing have received an impetus, thereby creating an image of a potential Pharma market and land
of opportunities
in the pharmaceutical division. Moreover the new Draft Drug Policy’ 2006 was released
Stock
Scan
during this quarter.
Upcoming Events
In Focus: Innovatives and Recent Trends of CT Scanner in Market
Introduction
A CT scan stands for Computed Tomography scan. It is also known as a
CAT (Computer Axial Tomography) scan. It is a medical imaging method
that employs tomography. Tomography is the process of generating a twodimensional image of a slice or section through a 3-dimensional object (a
tomogram). The medical device (the machine) is called a CTG scanner; it is a
large machine and uses X-rays. It used to be called as an EMI scan, because
it was developed by the company EMI. The CT scanner uses digital geometry processing to generate a
3-dimensional (3-D) image of the inside of an object.
Uses
CT scanner can be used to produce images of:
 Thorax - The equipment can be used to
demonstrate pulmonary lesions, kediastinal
masses, rib metastasis and lymph node
metastasis.
 Abdomen and pelvis - It can be used to
demonstrate liver tumours, pancreatic
tumours, adrenal tumours, enlarged intra
abdominal lymph nodes.
 Musculoskeletal system - It can be used to
demonstrate the bone architecture, spinal
fractures, extent of muscle tumours, and
extent of soft tissue masses.
 Radiotherapy - It can be used to plan the
radiotherapy field, to assess response to
radiotherapy in follow-up cases, to
demonstrate the recurrence of the malignant
disease.
9500
Future growth of
ct Scanners
8500
Rs bn

July 2011
7500
6500
2011
2015*
Sources: Market Resources; Cygnus;*Indicates
Estimated results
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd.
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-05, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
1
Pharma Professional
July 2011
Market Size
The market size of CT scanners in India was Rs5748.52m in 2010-11, a growth of 20% over the previous
year. The high-end CT scanner segment accounted for approximately 55% of the total market. Of this,
Cardiac high-end segment accounted for a major share that is 40%, amounting to Rs1315m in values. The
Non-Cardiac and Radiological high-end segment is valued at Rs485.26m and 15% share. The Value
segment has shown appreciable growth and accounted for 30% share of the total market, valued at
Rs1130m. The Entry Level segment held 10% of the market and valued at Rs5748.52m. There is a major
shift in demand towards high-end models in the Refurbished Equipment segment, which is valued at
Rs9945 by 2015 which is estimated the values.
Hazards of CT scan
CT scanners use intravenously administered contrast agents in order to provide superior image quality.
Hence, there is a low, but non-negligible level of risk associated with the contrast agents themselves.
Certain patients may experience severe and potentially life-threatening allergic reactions to the contrast
dye. The contrast agent may also induce kidney damage. The risk is high in patients who have preexisting
renal insufficiency, and diabetes, or reduced intravascular volume.
Recent Trends
Wider detector coverage
 State of the art: 64-slice CT has 3.2 to 4.0cm detector width
 Work-in-progress: 128-slice (expected 2007-2008) and 256-slice
CT (expected 2008-2009) for up to 16-cm-wide detector
coverage
Major Players
 Blue Star Limited
 GE Healthcare
 Siemens
 Neusoft
Multi-source CT
 Industry-first: Siemens dual source CT
 With gantry rotation speed near its maximum, this solution may be the only way to improve
temporal resolution
Workflow
 Post-processing software : Computer-aided reading (CAR) and Detection (CAD), Advanced
visualization and 3-D/4-D imaging
 More efficient scanner software
 Improved clinical applications, in particular cardiac imaging packages
Dose reduction
 Improvements in hardware allow faster procedures, noise reduction
 Advanced techniques and algorithms : Automatic exposure control, tube current modulation,
ECG pulsing
Multi-energy imaging
 Using a single X-ray source and multi-energy detector: Work in progress, e.g. Philips, GE
Tomosynthesis using flat-panel detector (FPD) technology expected to merge with computed
tomography (CT) technology in the long-term, pending improvements in FPD technology.
Outlook
CT scanner market is estimated to grow to Rs7560m by 2012 with CAGR of 18%. Hybrid scanners
comprising PET and CT image capabilities are the trend, but a modest growth rate is expected for multislice computed tomography scanners. The market is declining for single slice CT scanners where pricing
alone seems to determine competition. The US, Europe and Japan account for 85%. Market leaders are
GE, Siemens, Toshiba and Philips. The CT scanners market is estimated to increase by 15% in the
coming year.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
2
Pharma Professional
July 2011
News Briefs
Marketing
Americas
USA: Nanoink launches the Nanoarray Assay System
Nano BioDiscovery Division announced the launch of a new instrument system for nanoscale protein
analysis and discovery. Coupling powerful array deposition techniques with the latest generation of
fluorescent detection technologies, the NanoArray Assay System is a user friendly, affordable desktop
unit that can quickly and cost-effectively integrate into any proteomic lab. The platform is based on
NanoInk’s patented, tip-based Dip Pen Nanolithography technology, which can create highly
reproducible protein arrays over millimeter areas with nanometer precision and then fluorescently image
these nanoarrays at high resolution.
USA: ImaginAb, announces availability of protein radio labeling services for molecular imaging
ImaginAb, Inc. is pleased to announce the availability of custom radio labeling services for proteins,
peptides and other macromolecules. This is part of the company's ongoing initiative to broaden the range
of product and service offerings to the biopharma and research community and is synergistic with
existing activities in custom antibody fragment engineering. Over the past 18 months it has grown its core
antibody engineering program to over a dozen 'companion diagnostic' programs with pharmaceutical
companies in addition to its own internal pipeline.
USA: Biopharma revenues key to Pall’s Q3 gains
Pall’s biopharmaceutical business contributed revenue of US$197m (€136m) for the three months ended
April up just over 21% from that recorded in the comparable period in the previous fiscal year. This
growth, a part of 16.3% hike to US$368m in total life sciences revenues, maintains the pattern seen in the
previous quarter and reflects, according to Pall, the firm’s role in the expanding vaccine and plasma
products markets. Total revenue for the period was also up with the gains in life sciences revenues almost
being matched by Pall’s industrial business, which saw revenue grow 14% to US$341m.
USA: Symetic opens process tech demo lab
Symetic has opened a new lab facility to showcase its range of processing systems to the pharmaceutical
manufacturing, packaging and nutraceutical sectors. The 31,500sqft laboratory, in Wall Washington, US,
houses a demonstration area where pharmaceuticals firms can analyse their products and a separate unit
where they can conduct factory acceptance testing (FAT) on developmental processes. One of the key
features of the new facility is a live video feed that allows those unable to travel to Walla Walla to
demonstrations or application tests as those present and make observations and ask questions in real-time
while their product is being run.
USA: RxEvent launched to aid physicians, manufacturers and the US FDA
A new online adverse drug event (ADE) network will improve the quality of data and, ultimately, boost
drugmakers’ cost-efficiencies according to developer PDR Network. The RxEvent system is designed to
allow physicians to report adverse events via their electronic health records (HER) platforms. This data
can then be passed directly to drug makers and the US Food and Drug Administration (FDA). PDR, a
distributor of FDA-approved labelling data, alerts and REMS information, developed RxEvent in
partnership with Greenway Medical Technologies, American Pharmacists Association and athenahealth.
USA: Kareus Therapeutics enters strategic drug development alliance with Quintiles
Kareus Therapeutics a company focused on the development of novel therapeutics to address high unmet
medical need, announced a broad strategic alliance with Quintiles to progress the development of two of
Kareus’ pre-clinical programs through clinical trials. Under the terms of the alliance, Quintiles will make
an investment in Kareus in the US$ seven figure range, apportioned between an equity investment and
access to clinical service on a shared-risk basis. Following the investment by Quintiles, Kareus plans to
submit an investigational new drug (IND) application for KU-046, a first-in-class new chemical entity.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
3
Pharma Professional
July 2011
USA: Lamellar Biomedical Secures its First Orphan Drug Licence
Lamellar Biomedical Ltd announced that their lead clinical candidate LMS-611 for the treatment of
patients with cystic fibrosis has received Orphan Drug Designation from the European Commission. The
designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP)
within the European Medicines Agency (EMA) earlier this month. The designation of LMS-611 as an
orphan drug by the European Medicines Agency underscores the importance of developing effective
treatments for patients with cystic fibrosis, LMS-611 is developed from Lamellar’s proprietary inhaled.
USA: Pronova BioPharma's PRC-4016 to begin clinical trials for mixed dyslipidemia
Pronova BioPharma will announce pre-clinical results of PRC-4016, a new chemical entity for the
treatment of mixed dyslipidemia, and the Company is preparing to initiate clinical trials. Mixed
dyslipidemia is one of three main types of dyslipidemia, which is caused by an imbalance in the level of
blood lipids. Lipids, or fat molecules, include both cholesterol and triglycerides, and dyslipidemia has
been shown to play an important role in the development of cardiovascular diseases. Mixed dyslipidemia
is characterized by elevated triglycerides (TG) and low high-density lipoprotein-cholesterol (HDL-C) with
or without raised LDL cholesterol.
USA: CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service
CEVEC Pharmaceuticals and Catalent Pharma Solutions announced a joint commercial cell line
development service for pharma and biotech customers worldwide. The offering combines the benefits
of CEVEC’s human cell line, CAP-Technology, with Catalent’s GPEx (Gene Product Expression)
Technology to generate high expressing stable human cell lines in a much shorter timeframe than
traditional methods. Several months of testing convincingly showed combining CAP cells and GPEx
technology is a very powerful approach. It is a very complex protein produced in our human production
cell lines in a very short time frame.
USA: Sanofi-aventis enters into Research Collaboration to Develop Potential Treatments for
Hearing Loss
Audion Therapeutics announced that it has entered into a two-year agreement with Sanofi to develop
potential treatments for hearing loss through the optimization of small molecules by using a regenerative
medicine approach. This collaborative research will utilize technology developed at the Massachusetts Eye
and Ear Infirmary in the Eaton-Peabody Laboratory. Under the terms of the agreement, Sanofi has an
option to license technology rights from Audion related to research conducted under the collaboration.
This alliance with Sanofi validates our thinking around developing small molecule regenerative drugs for
the treatment of hearing loss.
USA: EPA Launches Searchable Database on Chemicals
The US Environmental Protection Agency has launched its Web-based chemicals database, ToxRefDB,
which allows anyone to search and download thousands of toxicity testing results on hundreds of
chemicals. This latest announcement is part of the EPA’s policy to increase the transparency of chemical
information. In January, the federal agency announced a new policy that gives consumers more access to
information on chemicals by rejecting a confidentiality claim by manufacturers on the identity of
chemicals. ToxRefDB provides detailed chemical toxicity data available public hazard, exposure, risk
assessment data and previous unpublished studies related to cancer, reproductive, and developmental
toxicity at your fingertips and in an accessible format.
USA: Zimmer launches new range of augments for knee revision surgery
Zimmer has launched a new range of Trabecular Metal Material augment shapes and cones to fill small to
large cavitary bone defects, provide a structural foundation to the existing bone and help support revision
knee implants. The new augments are designed for use with the NexGen Knee System. Trabecular Metal
material is a porous biomaterial that resembles the structure, function and physiology of trabecular bone.
According to Zimmer, the elasticity of Trabecular Metal Technology provides normal physiological
loading which has the potential to decrease stress shielding and improve long-term implant fixation.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
4
Pharma Professional
July 2011
USA: Shimadzu launched highly featured TOC-L Series systems
Shimadzu Medical Equipments Private Limited has launched a new series of combustion type analysers.
These Total Organic Carbon (TOC)-L Series systems have four models including PC-controlled and
separate versions. TOC-L Series systems can be used to supply pharmaceutical water. It considers 680
degree Celsius combustion catalytic oxidation method that can perfectly analyse all organic compounds. It
also supports every application to measure organic compounds available in pure or contaminated water
because of its measuring range of 4 µg/L to 30,000 mg/L. Apart from that, it can also measure liquid,
solid and gaseous specimen.
USA: NovaBone Products opens new R&D facility in Florida
NovaBone Products, which develops bone graft substitutes based on advancements in biomedical
engineering that meet the specialized needs of orthopedic and dental surgeons, has opened a new 3,500
square foot dedicated R&D facility in Gainesville, Florida. The new facility provides a platform for
NovaBone Products to implement its product development strategy. The company has recently named
Gregory Pomrink as VP of R&D. Prior to joining NovaBone Products, Pomrink worked at Orthovita,
Dentsply and Integra Life Sciences.
USA: Neurotech introduces Kneehab XP Quadriceps therapy system in US
Neurotech, a division of Bio-Medical Research (BMR), has introduced Kneehab XP, a surface
neurostimulation system to strengthen quadriceps muscles and improve knee stability after surgery in the
US. The Kneehab XP system is a conductive garment that features a hand-held controller that delivers
stimulation to the quadriceps area of the thigh. The FDA approved Kneehab XP incorporates Multipath,
a patented stimulation technology that stimulates the natural muscle recruitment sequence to maximize
fiber contractions. Kneehab is indicated for muscle re-education of the quadriceps, increasing range of
motion of the knee joint, preventing disuse atrophy in the quadriceps for early post-surgical quadriceps
strengthening.
USA: Abbott introduces FreeStyle InsuLinx in UK
Abbott has introduced FreeStyle InsuLinx Blood Glucose Monitoring System in the UK. The new
FreeStyle InsuLinx System comes with a mealtime (bolus) insulin calculator for calculating suggested
insulin doses. The bolus calculator feature is designed to help patients administer an accurately calculated
suggested dose of insulin to help maintain appropriate blood glucose levels. The new system also offers
other features such as a touch screen interface, automated logbook, personalization preferences and USB
connectivity for plug-and-play reports via the new FreeStyle Auto-Assist data management software.
USA: St Ann's Bay Hospital gets well-needed medical equipment
As the fastest-growing union in North America, the Service Employees International Union (SEIU) has
extended its reach to Jamaica with assistance to the St Ann's Bay Hospital. The SEIU Local 1
collaborated with Canada's Multi-Faith & Community Network and Miracle Centre Ministries to donate
more than 42 pieces of medical equipment to the hospital. The items included wheelchairs, resuscitators,
walkers, canes and support stands. These were received by senior medical officer of the St Ann's Bay
hospital, and the hospital's Chief Executive Officer Keith both thanked the SEIU team for the
contribution and described the items.
USA: Aquino turns over medical equipment to Manila hospital
The President Aquino presented the Sta. Ana Hospital with an endoscopy unit after he inaugurated the
hospital’s newly constructed additional five floors. The President, accompanied by various doctors and
Manila Mayor Alfredo Lim, toured and inspected the newly built 6th to 10th floor of the facility, located
at Manila’s Sta. Ana district. The President stated that the donation of the endoscopy equipment was one
way by which the national government was assisting local governments in improving health services.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
5
Pharma Professional
July 2011
USA: Tamale Hospital receives medical equipment
Tamale Teaching Hospital has received medical equipment, worth two million US dollars, donated by the
Children of Abraham, a group based in Indiana, USA. The equipments include, three cobe dialysis, a
machine used for removing waste from the kidney, oxygen tents, ventilators, Western Lloyd neurostat, xray view boxes, 11 patient chairs, wheel chairs, medical record rotating table top and bedside monitors.
Also, ventilators, suction vacuum pump, physical therapy table, mayo stand, 1,726 boxes of miscellaneous
medical supplies, stacker and office chairs and beds, among others.
USA: Bluetooth 4.0 will create smarter medical devices
The Bluetooth standards body has added support for two specific data types in the Bluetooth 4.0
specification: the Health Thermometer Profile and the Heart Rate Profile. This will give rise to wireless
devices that can help monitor and send health information from wearable sensors to smart phones and
central monitoring systems, proving Bluetooth still has legs. Expectations for such health devices are
high, predicted to be a US$2.1 billion industry by the end of this year and worth US$9.3 billion by 2014.
The Health Thermometer Profile and the Heart Rate Profile were built to enable the wireless monitoring
of body functions – in this case, body temperature and heart rate. While the Bluetooth SIG created the
technology, its members, consisting of the leading health, medical and fitness device manufacturers,
create the specific ways it will be used.
USA: Windows Embedded medical devices
Qiagen, a global provider of sample and assay technologies, and InHand Electronics, a provider of lowpower embedded systems to OEMs, have joined forces with Microsoft to create a cancer screening device
powered by Windows Embedded CE 6.0 R3. The careHPV Test effectively screens women for cervical
cancer and HPV even in regions of the world without access to electricity and running water. The
availability of the Windows Embedded-powered careHPV Test will help increase early detection of the
disease and provide test results to patients within a few hours instead of days.
Europe
UK: Russian Pharmaceutical Market Driven by Hepatitis C
An alarming number of Hepatitis C patients in Russia are driving the country's pharmaceutical industry,
with Roche and Schering-Plough benefiting particularly. According to the 'Russian Pharma Sector
Forecast to 2013' report compiled by industry intelligence firm RNCOS, augmented use of intravenous
drugs and high-risk sexual activities, combined with an unhygienic lifestyle, have caused the disease to
steadily increase in Russia. The report indicates that the market would grow at a CAGR of 9% during the
2009-2013 period, with Roche's Pegasys and Schering-Plough's PegIntron medications benefiting from
the increase.
UK: French Collaboration to Develop Parasite Vaccines
Genomic specialist Cellectis and biotech leader VitamFero have signed a research, development and
licensing partnership agreement for a new generation of attenuated vaccines. This agreement will grant
VitamFero access to Cellectis' proprietary meganuclease technology for the design and development of a
new generation of living attenuated vaccines. Under the five-year agreement, Cellectis will supply
VitamFero with pre-selected meganucleases for initial use in the development of vaccines against the
parasites responsible for toxoplasmosis and neosporosis, among others. The agreement represents an
important step, by getting access to Cellectis' intellectual propriety and strengthening its technological
potential in the modification of the genomes of apicomplex parasites.
India: Pfizer Settles Neurontin Suit
Pfizer has settled a dispute with Teva Pharmaceuticals regarding generic versions of epilepsy drug
Neurontin, ending a federal court trial. Pfizer had claimed that Teva and its Ivax unit produced copies of
the drug that infringed on a patent that does not expire until 2017. As a result, the company sought
compensation for lost profit after sales of the drug plunged dramatically from US$2.5 billion to US$150m
due to what Pfizer argues as a direct result of low-cost competition. Under the terms of the agreement,
Teva will continue to sell the copy under a licence from Pfizer, although financial details have not been
disclosed.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
6
Pharma Professional
July 2011
India: Pfizer Launches First Virtual Trial
Pfizer has announced that it is conducting the first-ever 'virtual trial', which will allow patients to
participate online from a remote location. The pilot project, initiated following a review from the US
Food and Drug Administration (FDA), will use mobile phone and web-based technology to collect
necessary data for the trial without clinic visits. The remote trial will access the safety and efficacy of
Detrol LA (tolterodine tartrate), a treatment for overactive bladder. Pfizer executive vice-president and
chief medical officer say that it is possible for patients to participate in clinical trials without having to
visit physical sites. Studies like this could make biomedical science much more accessible to people who
have long been excluded from or under-represented in clinical trials.
India: Pharmaceutical industry expected to register 12-14% growth in FY12
The domestic pharmaceutical industry is expected to increase by the growth rate of 12 to 14% in the
ongoing financial year, as stated by Executive Director, Indian Drug Manufacturers' Association (IDMA).
The pharmaceutical sector's total growth on year-on-year basis is to reach around 12 to 14%. By and
large, sector's growth in the export market stood by 20 %. In previous financial year, the growth of the
global pharmaceutical sector increased to Rs1000 billion and the domestic pharma market has surged to
Rs550 billion and the export market also grew to Rs450 billion. The focus areas of Indian pharmaceutical
sector, around 5% companies are giving focus in their R&D activities, while some companies are
spending more than 10% in their research and development.
India: Genome Foundation proposes to create more genome testing labs
Genome Foundation is planning to create genome testing laboratories in the remote areas in the country.
In this regard, it has submitted a proposal of Rs0.11 billion to the Department of Science and Technology
(DST). Genome Foundation is a non-profit organization that has several testing labs like at Kolar in
Karnataka and Kalwari in Uttar Pradesh. Now, it is expecting to find approval of the government for its
proposal to set up more testing labs in the far-flung areas across the country. The state government of
Andhra Pradesh has already allotted 4.3 acres of land in the city for the creation of a well-equipped testing
lab.
India: Drug companies reduce vaccine rates in developing nations
Numerous drug firms have bought down the prices of the vaccine in the developing world.
Pharmaceutical companies such as GlaxoSmithKline (GSK), Merck, Johnson & Johnson and SanofiAventis have decided to bring down the rates via the international vaccine alliance Gavi. GSK has stated
that it would be bringing down the price of its vaccine for rotavirus by 67% to US$2.50 per dose in the
poor nations. Rotavirus-related diarrhoea kills over 500,000 children every year. The vaccine will then be
subsidised by higher rates being charged in the rich nations.
India: Vertex Publishes Interim Results of Cystic Fibrosis Combination Therapy
Vertex Pharmaceuticals has announced the interim results of combination regimens of VX-770 and VX809, two drugs to treat cystic fibrosis, from the first part of a Phase II study. The first part of the study
enrolled and randomised 62 people with two copies of the mutation in the cystic fibrosis gene, and
demonstrated the safety and tolerability of the combination regimen with no serious side effects. The
Chief Scientific Officer and Executive Vice-President of global research and development, says that the
second part of the study will begin in 2012. The commonly reported adverse events include respiratory
symptoms.
India: Tata Chemicals Net Rises 8%
Tata Chemicals has consolidated net profit for the last fiscal year rose 8% to Rs6.53 billion (US$145.3m)
from 6.06 billion rupees the previous year. Consolidated sales for the year through March grew by 15% to
Rs108.95 billion from Rs94.48 billion, the maker of fertilizers and inorganic chemicals. Total costs for the
last fiscal year increased to Rs96.48 billion from Rs81.51 billion a year earlier. Tata Chemicals its net profit
for January-March rose 14% to Rs1.46 billion, while its sales for the quarter climbed 16% to Rs26.58
billion. The Company said its board has recommended a dividend of Rs10 per share.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
7
Pharma Professional
July 2011
India: MMTC floats tenders for complex fertilizers import
Government-owned trading firm MMTC Limited has invited tenders for the import of three grades of
complex fertiliser so as to meet the fertiliser demand in the current kharif season. In India, the Kharif
season starts with the start of the South-West monsoon from June, while harvesting picks up from
October and crops like paddy, pulses and oilseeds are largely grown during this season. The prospective
bidders are required to submit furnish details on the quantity of NPK complex fertilisers they want to
supply. The shipments should start between July and September and they are to be delivered at the Vizag,
Kandla, Rozi and Kakinada ports.
India: Blue Star Infotech unveils Oracle Accelerate Solution to capture Indian chemical sector
Blue Star Infotech Ltd (BSIL), provider of outcome-based IT solutions, has unveiled an Oracle
Accelerate Solution for the Oracle E-Business Suite with the aim to tap the Indian chemical industry.
BSIL has all the needed qualifications to implement Oracle Applications using Oracle Business
Accelerators for the Indian market. It will be using OBA for Oracle E-Business Suite along with its
domain knowledge of the chemical industry. Moreover, the firm will have the capacity to bring down the
ERP implementation costs by 25-40% and also the implementation time by 30-40% for the chemical
industry. The company is engaged in developing information technology (IT) solutions for enterprises,
and building software products for independent software vendors.
India: MMTC invites bids for importing 4,300 tonnes of urea
Minerals and Metals Trading Corporation of India (MMTC), a state-run trading company, has invited bids
for supplying 4,300 tonnes of urea to numerous industries. The firm has also stated that the net
consignment, 3,600 tonnes of urea is to be discharged at the Nava Sheva port near Mumbai, 400 tonnes
at the Mundra port in Gujarat, 100 tonnes at the Inland Container Depot (ICD) in Tughlakabad and 200
tonnes at the Chennai port.
India: Kerala govt cancels HIL licence to manufacture pesticide endosulfan
The State Government has cancelled the licence of Kochi-based Central Government-run Hindustan
Insecticides Limited (HIL) to manufacture pesticide endosulfan. The Kerala State Pollution Control
Board has issued the closure notice to HIL. However, the company is allowed to manufacture other
products but its endosulfan plant will remain closed as the pesticide is blamed for almost 500 deaths in
the state since 1995. After the discussions between the Chief Minister, Health Minister and the
representatives of the HIL management and the employees’ union, the company will dispose the
pesticide-laden solid waste dumped in the compound in two phases. The phase I is scheduled to be
completed within a week and the phase II will be completed in seven months.
India: Excel Crop stops production, sale of Endosulfan
Excel Crop Care Ltd, a manufacturer of crop protection products has stopped the production and sale of
pesticide Endosulfan across the India as the Supreme Court has ordered a countrywide ban on it. As the
ad-interim order has been issued during the peak sale season, the performance of the Company in the
short term will be adversely affected," according to the statement issued by the company. However, to
rationalise the inverse impact on its business, the company is planning to revise its sales plan and
marketing strategy. CPIM's youth wing Democratic Youth Federation of India (DYFI) has filed a writ
petition before the apex court seeking a ban on sale and production of Endosulfan across the country.
India: MMTC want to import di-ammonium phosphate
Minerals and Metals Trading Corporation of India (MMTC) has floated bids for the import of diammonium phosphate (DAP) just ahead of the commencement of the kharif season in June. The bids
will be closing on May 30. The decision on awarding the tender will also be taken on the same day, stated
MMTC. The firm has also asked the bidders to quote the quantity of DAP they plan to supply. The
shipment period for the consignment is during May-September, 2011. The contracted supplies would
have to be delivered at the Kandla, Rozy, Kakinada, Vizag, Tuticorin, New Mangalore and
Krishnapatnam ports.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
8
Pharma Professional
July 2011
India: Jyothy Labs completes acquisition of 50.97% stake in Henkel India
Jyothy Laboratories has completed acquiring 50.97% stake in Henkel India Ltd. (HIL), taking its total
shareholding in the Chennai-based firm to 65.88%. The company has acquired 5.94 billion shares
aggregating to 50.97 stake in Henkel India, Jyothy Laboratories says in a filing to the Bombay Stock
Exchange (BSE). This is subsequent to its announcement last month that it would buy out Germanybased Henkel AG & Co’s stake in HIL for Rs1.19 billion. The acquisition, Jyothy Lab has total of 76.70
million shares representing 65.86% stake in Henkel India, the filing added. The company had earlier
bought 14.9% stake in HIL from the Indian promoter Tamilnadu Petroproducts for around Rs600m.
India: Lanxess selects Singapore for setting up world’s largest Nd-PBR plant
Lanxess has selected Singapore as the site for its new neodymium polybutadiene rubber (Nd-PBR) plant.
The company plans to invest roughly Euro 200-mn in a 140,000 metric tons per annum facility on Jurong
Island Chemical Park. The facility will be the largest of its kind in the world. The plant is expected to start
up in the first half of 2015. A corresponding memorandum of Understanding (MoU) was signed between
Lanxess CEO and Chairman of the Singapore Economic Development Board (EDB). It is only one year
since it has broken ground for its butyl plant in Singapore. Now it is ready to move forward with the
second largest investment project in our history.
Mergers & Acquisitions
Americas
USA: Zealand Pharma and Boehringer Ingelheim enter into a licence and collaboration
agreement to treat Type-2 diabetes and obesity
Zealand Pharma and Boehringer Ingelheim jointly announced an exclusive global licence and
collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of
patients with Type-2 diabetes and patients with obesity. As part of the agreement, Boehringer Ingelheim
obtains global development and commercialisation rights to ZP2929, Zealand Pharma’s lead
glucagon/GLP-1 dual agonist drug candidate. Zealand Pharma will be responsible for conducting the first
Phase I study with ZP2929. Depending on the achievement of pre-defined development, regulatory and
commercial milestones, Zealand Pharma is eligible to receive payments for ZP2929 and may also receive
additional milestone payments if other products covered by the collaboration are advanced through
development.
USA: GEO Specialty Chemicals to acquire UK-based monomer business from BASF
GEO Specialty Chemicals Inc has inked a deal with BASF to acquire the Bisomer monomer business
(hydroxy methacrylates, multifunctional methacrylates and speciality adducts) and conventional contact
lens business of Cognis UK. The transaction includes a manufacturing facility in Hythe, England that
produces hydroxy methacrylates, multi-functional methacrylates (MFM) and speciality adducts
polyalkylene glycols (PAG) and PAG-based lubricants. This acquisition represents an important strategic
addition to GEO’s Paints & Coatings business group and it significantly expands its global manufacturing
and R&D capabilities, says the Chief Executive Officer of GEO.
USA: Momentive and SSF collaborate on medical devices
Momentive Performance Materials Inc. and Specialty Silicone Fabricators plan to collaborate to develop
combination products for medical devices manufacturers. The companies announced that the effort will
bring together Momentive’s advanced silicone elastomer technology with SSF’s expertise in silicone
extrusion and medical device assembly. Silicone is an ideal matrix material to consider for a wide range of
healthcare applications, and the firms UV cure technology will enable manufacturers to consider a much
broader range of ingredients in their silicone mixtures. SSF plans to expand its API/drug eluting device
production into another clean room that will house its own extrusion line and a larger press to meet
growing customer demand.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
9
Pharma Professional
July 2011
USA: Synthes to be acquired by Johnson and Johnson in US$21 bilion takeover
The US healthcare corporation Johnson and Johnson has agreed to buy the Swiss orthopaedic implant
manufacturer Synthes in a deal worth US$21.3 billion (£13bn). The deal is due to complete in the first
half of 2012, subject to shareholder and regulatory approval. Some have speculated that this helps
Johnson and Johnson manage the product recalls it has had to deal with in the last year and Synthes has
had a reputation as having the highest profit margins in the industry. The acquisition may push Johnson
and Johnson’s share of the orthopaedic trauma market to around 54%, a market which is expected to
grow faster than that for hip and knee replacement, and will also increase their presence in the market for
spinal implants.
USA: Bacterin signs contract with ROi
Bacterin International has agreed to provide the OsteoSponge product line, OsteoSelect DBM Putty,
milled and traditional allografts and the Elutia Coated Wound Drain to Resource Optimization and
Innovation’s (ROi) nationwide network of hospitals and medical practices. Bacterin claims its proprietary
methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and
promote bone and other tissue growth. The products are used in a variety of applications including
enhancing fusion in spine surgery, relief of back pain with a facet joint stabilization, promotion of bone
growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral
repair in knee and other joint surgeries.
USA: D Medical enters into agreement to sell NextGen Biomed
D Medical has signed a definitive agreement with a third party for the sale of its holdings in its publicly
held subsidiary NextGen Biomed. D Medical will transfer its holdings in NextGen in exchange for NIS
5.5m in cash. D Medical CEO reported that they believe that the additional resources that the completion
of this transaction will help them to build upon that momentum. Through its subsidiaries, D Medical is
engaged in the research, development, manufacture and sale of innovative products for diabetes treatment
and drug delivery. D Medical products include durable and semi-disposable insulin pumps, which
continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology.
USA: HealthTrust enters into spine implant agreement with Pioneer Surgical
HealthTrust Purchasing Group has entered into a spine implant agreement with Pioneer Surgical
Technology, a provider of orthopedic, spine and biologic systems. HealthTrust is a group purchasing
organization that supports nearly 1,400 not-for-profit and for-profit acute care facilities, as well as 10,600
ambulatory surgery centers, physician practices and alternate care sites. Pioneer Surgical will provide
members of HealthTrust access to premium, medical devices for spinal fusion, including cervical and
lumbar plates, pedicle screw systems, interbody devices and a minimally-invasive lateral approach system,
Cross-Fuse. Some other products are Streamline TL, a thoracolumbar spinal fixation system, and
SlimFuse, an anterior cervical plate system.
USA: Verisante signs asset purchase agreement with Perceptronix Medical
Verisante Technology, a provider of systems for the early detection of cancer, has entered into an asset
purchase agreement with Perceptronix Medical (PMI) under which Verisante has rights to PMI's ClearVu
and ClearVu Elite endoscopy systems which are used to detect early lung cancer. The ClearVu system is a
simultaneous white light and fluorescence real time video accessory which is used with a fiberoptic
bronchoscope for lung cancer examinations. The ClearVu Elite has the addition of reflectance and
fluorescence spectral analysis to assess the malignancy potential of suspicious lesions. PMI's technology is
complementary to the Verisante Core which uses rapid Raman spectral analysis for the detection of lung
cancer.
USA: Ortho-McNeil-Janssen Pharmaceuticals Terminates Diabetes Research Agreement
Ortho-McNeil-Janssen Pharmaceuticals, a Johnson & Johnson company, has terminated its agreement to
develop and commercialise a vaccine for type 1 diabetes. The termination follows last month's evaluation
of results of a Phase III study, which showed that the 'Diamyd' vaccine did not reach its primary efficacy
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
10
Pharma Professional
July 2011
endpoint of beta cell function at 15 months in patients newly diagnosed with the disease. The agreement
was made in June 2010, when Diamyd Medical received a non-refundable upfront payment of US$45m
and the parties began sharing the costs of the programme equally. Following the termination, Diamyd
says it has regained control of all rights regarding Diamyd and active substance GAD65.
USA: Lilly and Synthes Sign Collaboration Agreement
Eli Lilly has signed a worldwide collaboration agreement with medical device manufacturer Synthes to
address the needs of patients with bone disorders. The agreement will allow the joint development of
early stage compounds to be used by patients in the care of orthopaedic surgeons, including those who
suffer from osteoporosis, and the two companies will collaborate to develop osteoinductive medications.
Both companies will also conduct and fund work into evaluating Lilly's osteoporosis drug Forteo for
other orthopaedic uses, while Forteo will also be co-promoted in the US to orthopaedic surgeons under
the agreement.
Asia-Pacific
India: BASF and Ineos sign joint venture contract for Styrolution
BASF and Ineos Industries Holdings Ltd. have made an important step towards the establishment of the
joint venture company, Styrolution. The companies signed a joint venture contract, which regulates the
formation of the joint venture company. BASF and Ineos plan to combine their global business activities
in styrene monomers (SM), polystyrene (PS), acrylonitrile butadiene styrene (ABS), styrene-butadiene
block copolymers (SBC) and other styrene-based copolymers (SAN, AMSAN, ASA, MABS) as well as
copolymer blends into the new joint venture. The company headquarters will be located in
Frankfurt/Main, Germany. In the joint venture 50% of the shares will be owned by BASF and 50% by
Ineos.
India: Iran seeking partner for Hormuz fertiliser plant
Iran has announced that it is seeking a new partner to replace Oman in its US$800m Hormuz urea
fertiliser plant, according to leading chemical industry information provider, Platts. The project was being
carried out in a 50:50 joint venture between Iran’s National Petrochemical Company and the Oman
Government. However, Oman has showed reluctance to take part in the project after it signed an
agreement with National Petrochemical Company.
Investments
Americas
USA: APP invests US$38m to boost injectable generics capacity
APP Pharmaceuticals will invest US$38m to boost its manufacturing capacity for injectable generic drugs
at its facility in Grand Island. The investment will add 13,000 sq of manufacturing space and six new
production lines in a project expected to start later this month and take around two years to complete.
APP, which employs 580 people at the facility, expects to hire an additional 90 staff. The plant was built
in 1970 and has undergone a number of expansions, most recently in 2005 when APP added
manufacturing capability for aseptic filling and packaging for pharmaceuticals. APP, which was bought by
and makes anti-infectives as well as products for critical care, analgesia, anaesthesia and oncology at the
site and claims that growing demand for such drugs, was a key driver for the decision to invest.
USA: Tycoon to invest millions in growing biopharma industry
Biopharmaceuticals are medical drugs produced using biotechnology. They are produced by means other
than direct extraction from a native (non-engineered) biological source. Business News understands that
Mellon, whose wealth is worth £550 million, will be investing in the company himself as it undertakes a
pre-flotation fund raising. The money has been investing in United States biopharma companies for the
last two years and believes that it is an area set for explosive growth. Biopharma Investments will be
investing alongside personal investments in this sector over the coming years. Although any investments
carry a certain amount of risk it is acknowledged that research into medicines and pharmacy is something
of a boom area.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
11
Pharma Professional
July 2011
USA: Vetter Invests in Additional Lyophilization Capacity
Vetter has installed three additional state-of-the-art lyophilizers at the company’s Ravensburg Vetter
South facility, nearly doubling its number of freeze-dryers. Altogether, the site will be able to produce up
to 24 million lyophilized units annually. The new equipment increases the number of lyophilizers across
all Vetter facilities by 30%. The company made the investment to meet anticipated future demand for
aseptically filled biologics and other sensitive compounds, which often require lyophilization to prolong
shelf life and potency. In the last three years, more than 30% of all novel drugs approved in the United
States were lyophilized, according to the US Food and Drug Administration. Experts predict continued
growth.
USA: Investment €1.1 million boost for medical devices firm
Cork-based Radisens Diagnostics recently secured investment worth up to €1.1 million through Kernel
Capital and the Bank of Ireland MedTech Accelerator Fund (€500,000), private funding and Enterprise
Ireland. The start-up firm has made substantial progress in developing a ‘point of care’ test which see the
future diagnosis of multiple infectious diseases, cancers, cardiac markers and viruses completed within
minutes – saving lives, reducing patient waiting lists and ensuring optimal use of time in the process.
Attracting a high-calibre investor such as Kernel Capital at this early stage in Radisens’ development
significantly endorses our unique value proposition, in what is an US$8 billion market segment. Radisens’
innovative convergence of medical diagnostics and consumer electronics fields will transform this sector,
uniquely addressing clear unmet clinical and commercial needs.
USA: Medical device sterilization firm Sterilucent plans new investment US$2m
A medical device sterilization business that has focused on serving the military could raise up to US$2m,
according to a federal regulatory filing. Sterilucent is developing a quick, efficient and portable
sterilization process that caught the eye of the military, which had trouble deploying sterilization
equipment to forward bases because of the size of the machinery. The company won a five-year contract
to deliver its technology to the US Army Combat Casualty Care Hospitals. Sterilucent has operated
through a mix of federal contracts, earmarks and grants; some small early stage investments; and revenue
from the coatings technology that spawned this business.
USA: UK invests in seven personalised medical projects
The Medical Research Council and Technology Strategy Board in the UK have announced that they will
jointly invest £3.7m in seven major research projects, which will study and develop personalized
medicine. The projects will be lead by pharmaceutical companies AstraZeneca UK, GlaxoSmithKline, Ig
Innovations, Janssen UK and Randox Laboratories. Four of the projects will develop the use of
biomarkers to predict how groups of patients respond to inflammation and immunology therapies. In this
way, therapies could be given only to relevant patient subgroups for better results in alleviating symptoms
and side effects. The other three projects relate to developing business models to help determine the best
ways to co-develop drugs and companion diagnostics.
Asia-Pacific
India: Evonik invests 150 mn begins production at new monosilane plant in Japan
German chemical group, Evonik Industries, and its partner Taiyo Nippon Sanso Corporation (TNSC) has
officially started up the new integrated production facility for monosilane and ‘Aerosil’ in Yokkaichi,
Japan. The project involved investment of around Euro 150-mn and the facility was the company’s largest
single project in 2010. The process used to produce monosilane at this new plant was developed by
Evonik, which already operates a facility using this technology in Rheinfelden (Germany). The new plant
in Yokkaichi will serve the Asian market with electronic-grade monosilane. This substantial investment in
Japan expands our significant market and technology position in the future-oriented solar energy market.
India: Elder Pharma plans Rs1.30 billion investment in research facility
Elder Pharma has announced its plans to invest about Rs1.30 billion in its research facility, over the next
two-three years. In 2010, the company has upgraded the facility in order to develop new drug delivery
systems. In the current year, the company is planning to increase the team in order to develop and market
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
12
Pharma Professional
July 2011
products by the company and its in-licensing partners. Presently, the company has nearly 25 licensing
partners, whose products are marketed by Elder Pharma. The company is also considering to start
collaborative research work in some of these partnerships. The company is primarily focused on the areas
such as prescription products in women's health, nutraceuticals and pain management. The company is all
set to market its Rs2 billion Shelcal in Sri Lanka, Bangladesh, and among other markets.
Others
Americas
USA: Cancer Protein Discovery May Aid Radiation Therapy
Scientists at Dana-Farber Cancer Institute have uncovered a new role for a key cancer protein, a finding
that paves the way for more-effective radiation treatment of a variety of tumors. Many cancers are driven
in part by elevated levels of cyclin D1, which allow the cells to escape growth controls and proliferate
abnormally. Nature, researchers discovered that cyclin D1 also helps cancer cells to quickly repair DNA
damage caused by radiation treatments, making the tumors resistant to the therapy. Based on this finding,
the researchers made cancer cells more sensitive to several cancer drugs and to radiation by using a
molecular tool to lower the cancer cells' cyclin D1 levels.
USA: Mitsubishi Chemical to enhance PVC production capacity in Thailand
Tokyo-headquartered Mitsubishi Chemical Corporation (MCC) will enhance the production capacity of
its poly vinylchloride (PVC) facility in Thailand. Work on capacity expansion will begin from April 2012.
The capacity will be increased to 15,000 tonnes per annum (tpa) from the existing capacity of 4,000-tpa.
The corresponding investment has been planned at approximately Yen 500-mn (about US$6.2m).
Asia-Pacific
India: WTO demands from Indian govt for offering subsidy on indigenous ammonium sulphate
World Trade Organisation (WTO), the primary international body to help strengthen free trade, has asked
India to give details for offering subsidy on only indigenous ammonium sulphate and not on the imported
fertiliser. Presently, the Indian government has kept the imported ammonium sulphate out of the
boundary of Nutrient-Based Subsidy (NBS) policy. The Fertiliser Ministry is looking at the points that
have been raised by WTO and will soon respond to them. India offers subsidy on 22 grades of
phosphorous and potassium fertilisers under the NBS Policy on the indigenous and imported fertilisers.
The Centre has set the subsidy of Rs5,979-per tonnes for the indigenous produce so that fertiliser is
available at affordable price in the Indian market.
India: Vicus Therapeutics starts phase II study of VT-122
The biopharmaceutical company Vicus Therapeutics has started a new phase II study of VT-122, by
which it hopes to find a breakthrough in liver cancer medication. VT-122 combines two oral generic
drugs such as etodolac (a Nonsteroidal anti-inflammatory drug-NSAID) and propranolol. The company is
seeking expertise help of pharma-biotech industry and medical institutions for the development and
advancement of VT-122. According to the, Director, India Operations of Vicus Therapeutics, all its
products can be considered under generic drugs and they are able to improve treatment quality and
increase the duration of therapy by lowering the evolution of disease. For the new phase II study of VT122, the company has already completed pilot study.
India: Glenmark wins final nod from US Food and Drug Administration for Mupirocin ointment
Glenmark, has bagged final approval from the United States Food and Drug Administration (USFDA)
for its generic Mupirocin ointment, which is used for the treatment of bacterial skin infections. Glenmark
Generics Inc, an US arm of Glenmark Generics, has won a final abbreviated new drug approval (ANDA)
from USFDA for Mupirocin Ointment. According to a statement from Glenmark, “Based on IMS health
data for the 12-month period ending March 2011, Mupirocin ointment garnered annual sales of US$55m
and achieved a 9% increase in growth compared to the same period last year. The ointment is available in
a 22-gram tube. The firm's present portfolio includes 68 products authorised for distribution in US
market.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
13
Pharma Professional
July 2011
India: ICRA forecasts high good growth rate for research and manufacturing services
Investment Information and Credit Rating Agency (ICRA) of India Limited has forecast that the market
of Indian Contract Research and Manufacturing Services (CRAMS) would resister a compound annual
growth rate (CARG) of 41.4% during the financial year 2011-12.According to ICRA, the total market size
would touch the mark of US$7.6 billion with this growth rate. The country is expected to gain good
number of United States Food and Drug Administration (US FDA) approvals and more skilled work
force during the stipulated period. Furthermore, the inherent cost effectiveness is likely to support the
country’s pharma industry for achieving the global pharma outsourcing market of US$67 billion.
FDA Approvals
Americas
USA: FDA Approves Drug for Epileptic Seizures
The US Food and Drug Administration (FDA) has approved the use of Potiga (ezogabine) tablets to treat
seizures associated with epilepsy in adults. Potiga, manufactured by GlaxoSmithKline and Valeant
Pharmaceuticals International, is the first neuronal potassium channel opener developed to treat partial
seizures, the most common type of seizure seen in people with epilepsy, a disorder in which there is
abnormal or excessive activity of nerve cells in the brain. Although the mechanism of action is not firmly
established, the drug may act as an anticonvulsant by reducing excitability through the stabilisation of
neuronal potassium channels.
Asia-Pacific
India: Johnson & Johnson Seeks 11 New Drug Approvals
Johnson & Johnson is seeking approval for 11 new drugs by 2015 in an attempt to revive its
pharmaceuticals business, including medications for Alzheimer's, diabetes and arthritis. Generic
competition to the company's prescription medicines have diminished Johnson & Johnson's earnings
over the past two years, and 30 approvals for product line extensions are also being sought. The company
expects US regulators to make a decision this year over its blood-clot preventer Xarelto, to be used in
patients undergoing hip and knee replacements, whereas its new Type II diabetes treatment canagliflozin
could receive US and European approval next year.
Exports & Imports
Asia-Pacific
India: Fertilisers and Chemicals Travancore to import urea from Kuwait
Fertilisers and Chemicals Travancore (FACT) has announced to import 33,000 tonnes of urea from
Kuwait. The consignment of urea is being shipped through 'Star Reliance' and is expected to reach Kochi
port by next week. The urea import is targeted to provide necessary fertilisers to farmers before the
monsoon and a major portion of the urea would be distributed to the farmers in the state.During the
quarter ended March 2011, the company has reported a loss of Rs272.3 billion as against a profit of
Rs930 billion in the same quarter last year.
Operations
Asia-Pacific
India: AstraZeneca Agrees to Pay US$250,000 to Settle Sex Discrimination Lawsuit
AstraZeneca, one of the largest pharmaceutical companies in the world, will pay US$250,000 to 124
women who were subjected to pay discrimination while working at the corporation's Philadelphia
Business Center in Wayne, Pa. The action resolves a lawsuit filed by the US Department of Labor in May
2010 alleging that the company discriminated against female sales specialists by paying them salaries that
were, on average, US$1,700 less than their male counterparts. The department's Office of Federal
Contract Compliance Programs conducted a scheduled compliance review of the business center in 2002.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
14
Pharma Professional
July 2011
Product Focus – Exelon
Introduction
Exelon (Rivastigmine Tartrate) is a parasympathomimetic or cholinergic agent
used for the treatment of mild to moderate dementia of the Alzheimer’s type
and dementia due to Parkinson's disease. It is an AChE inhibitor that works by
preventing the breakdown of a chemical called acetylcholine. Other dementia
drugs in the market are Pfizer’s Aricept and Reminyl. The molecular formula of
the drug is C14H22N2O2.
Working of Exelon
Exelon improves the function of nerve cells in
the brain. It works by preventing the
breakdown of a chemical called acetylcholine.
People with dementia usually have lower levels
of this chemical, which is important for the
processes of memory, thinking, and reasoning.
Side effects may include nausea and vomiting.
Administration with a transdermal patch has
fewer side effects compared to oral.
Elimination is through the urine. It has likely
relatively few drug-drug interactions.
Drug Brand Name
Active Ingredient
Company Name
Chemical Type
Drug Dose & Type
Patent Rights
Patent Expired
Drug Details
Exelon (Rivastigmine Tartrate )
Rivastigmine
Novartis
Novel Molecular Entity
Capsule with 1.5mg, 3mg, 4.5mg
and 6mg strength, twice-daily; or
Oral Tonic (2mg/mL) or
Transdermal Patches
Yes
Aug 2014
Side effects of Exelon
People with select biological conditions should take Exelon under doctor’s supervision. These conditions
include heart rhythm disorder such as "sick sinus syndrome" (slow heartbeats), an enlarged prostate,
urination problems, asthma, obstructive pulmonary disease, or a seizure disorder such as epilepsy. Exelon
is usually taken twice a day, in the morning and evening in the capsule form or in oral solution form. The
strength of oral solution form is 2 mg/mL, while that of capsule form are 1.5 mg, 3 mg, 4.5 mg and 6 mg.
Rs bn
Neurodegenerative disease scenario
15
Neurodegenerative disease (NDD) is a general
NDD sales In Market
term for a number of disorders that have
different symptoms and effects, all of which act
through the mechanism of compromising the
brain's capacity to control itself or the body by
damaging cells known as neurons that facilitate 10
normal brain function. Alzheimer's disease (AD)
is the world's leading cause of dementia and the
most prevalent NDD. Around 50-75% of
dementia is estimated to be caused by this
disease. Parkinson's disease (PD) is the world's
5
second commonest form of NDD. Parkinsonism
2011
2013*
is a term for a group of disorders that result in
symptoms similar to those seen in classic PD Sources: Market Resources; Cygnus
NDDs are primarily diseases of older people. Research;*Indicates Estimated results
With the world's population living longer, the
numbers of sufferers are set to rise over the next several decades. NDDs constitute a disease category
that the World Health Organization (WHO) calculates will become the world's second leading cause of
death by the year 2040, overtaking cancer. Onset of AD most commonly occurs after 65 years of age
(only 2% of dementia occurs in patients under 65. Patients are most commonly treated for AD with a
class of drugs known as AChE inhibitors, such as Eisai/Pfizer's Aricept (donepezil) and Novartis’
Exelon. Aricept is the global number-one AD drug, worth US$1.8 billion in 2004. The next largest brand
was Novartis' Exelon (rivastigmine), another AChE inhibitor.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
15
Pharma Professional
July 2011
Market scenario
Rs m
Total neurodegenerative disease (NDD) product
700
Demantia Drugs In market
sales more than doubled in dollar terms in the
period 2010-2011 to reach almost US$6.8 billion.
The sales are expected to rise to over US$10
billion by 2013. Neurodegenerative diseases
500
(NDD) are destined to become the next great
health crusade over the next several decades. This
will support sustainable long-term sales growth of
300
NDD products. Growth in the Alzheimer's
market will be driven by the launch of new types
of drugs including GABA receptor modulators,
anti-amyloid protein agents and nicotinic and
100
cholinergic receptor agonists. While growth in
2011
2013*
the Parkinson's market will be in the medium to
long term driven by the launch of glutamate
Market Resources; Cygnus
receptor modulators, dopamine receptor agonists Sources:
Research;*Indicates Estimated Results
and reuptake inhibitors, and andrenergic and
adenosine antagonists. The US is the world's single largest NDD products market, worth nearly US$3.3
billion in 2011. Japan and Germany were the next biggest markets. As per the IMS June 2011 Moving
Annual Total, the annual sales of Exelon in the US reached US$200m. Exelon’s worldwide sales in 2013
reached around US$625m.
Indian scenario
Among developing nations, India is the only one where there are as many as six out of the world's 10
biggest pharmaceuticals companies. These companies account for roughly 62% of the total turnover of
pharmaceuticals MNCs in India. These MNCs include Glaxo India, Hoechst Marion Roussel, Novartis
India, Pfizer, SmithKline Beecham Pharmaceuticals and Wyeth Lederle. MNCs look at India for volume
growth and because it is critical to launch new drugs at a reduced time lag. Slower growth in developed
markets and heavy generic (off-patent drug) competition has also made the Indian market important.
Currently, the market for moderate to severe Alzheimer's dementia is largely untapped in India with Sun
Pharma recently launching its own product. The dementia drugs market in India is estimated to have
grown from about Rs300m in 2010 to about Rs1600m in 2015.
Outlook
India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in
terms of value. The Indian pharmaceuticals market is expected to reach US$55 billion in 2020 from
US$12.6 billion in 2010. Due to increase in the population of high income group, there is every likelihood
that they will open a potential US$8 billion market for multinational companies selling costly drugs by
2015. The domestic pharma market is estimated to touch US$20 billion by 2015. The healthcare market in
India is to reach US$31.59 billion by 2020. The sale of all types of pharmaceutical drugs and medicines in
the country stands at US$ 9.61 billion, which is expected to reach around US$19.22 billion by 2012.
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
16
Pharma Professional
July 2011
Stock Scan
Relative Market Cap Performance
110
100
90
BSE Sensex
Piramal
C ipla
Relative Market Cap Performance
15/06/11
14/06/11
13/06/11
10/06/11
09/06/11
08/06/11
07/06/11
06/06/11
03/06/11
02/06/11
01/06/11
31/05/11
30/05/11
27/05/11
26/05/11
25/05/11
24/05/11
23/05/11
20/05/11
19/05/11
18/05/11
17/05/11
16/05/11
80
BSE Sensex
110
SHASUN
AUROBINDO
100
90
15/06/11
14/06/11
13/06/11
10/06/11
09/06/11
08/06/11
07/06/11
06/06/11
03/06/11
02/06/11
01/06/11
31/05/11
30/05/11
27/05/11
26/05/11
25/05/11
24/05/11
23/05/11
20/05/11
19/05/11
18/05/11
17/05/11
16/05/11
80
Source: BSE India; Cygnus Research
Index
BSE (Points)
CIPLA (Rs)
PIRAMAL (Rs)
SHASUN (Rs)
AUROBINDO (Rs)
Index
BSE (Points)
CIPLA (Rs)
PIRAMAL (Rs)
SHASUN (Rs)
AUROBINDO (Rs)
1st Week (16 -23 May 2011)
Opening Closing Var(%)
18345.03 17993.33
-1.92
304.20
309.55
1.76
412.95
372.45
-9.81
81.50
84.95
4.23
194.55
175.55
-9.77
2nd Week (24th May-30th June 2011)
Opening
Closing
Var(%)
18011.97
18232.06
1.22
314.55
329.55
4.77
363.95
371.45
2.06
80.75
76.45
-5.33
168.70
171.90
1.90
3rd Week (31st May -6th June 2011)
Opening
Closing
Var(%)
18503.28
18420.11
-0.45
326.10
331.60
1.69
369.45
370.25
0.22
78.65
75.15
-4.45
176.65
174.20
-1.39
4th Week (7-15th June 2011)
Opening
Closing Var(%)
18495.62 18,132.24
-1.96
337.85
333.00
-1.44
369.00
368.80
-1.44
75.20
78.20
3.99
181.00
177.70
-1.82
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
17
Pharma Professional
July 2011
Upcoming Events
1.
Event
Date
Venue
Highlights
2.
Contact
Details
Event
Date
Venue
Highlights
3.
Contact
Details
Event
Date
Venue
Highlights
4.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
5.
Event
Date
Venue
Highlights
Contact
Details
P-Mec Japan
Jul 13-15, 2011
Intex Osaka Osaka, Japan
It is the abbreviation of Pharmaceutical Machinery & Equipment Convention,
which is the exhibition of machine and equipment for pharmaceutical studies
development and manufacturing. P-Mec Japan will be held at Intex Osaka.
CMP Information Industrieweg 54, P.O. Box 200, 3600 AE, Maarsen, The
Netherlands; Tel:+(31)-(346)-559444; Fax:+(31)-(346)-573811
International Modern Hospital Show
Jul 13-15, 2011
Tokyo International Exhibition Center (Tokyo Big Sight) Tokyo, Japan
It is the only trade show in Japan which is open to the dealers, buyers, doctors,
nurses, and medical-related industry people (not open to the public). Over 360
companies participated in IMHS 2010.
Nippon Omni-Management Association, 3-11-8 Sendagaya, Shibuya-ku, Tokyo,
Japan; Tel:+(81)-(3)-34324720; Fax:+(81)-(3)-34324730
WORLDx Congress 2011
Jul 18-20,2011
Hyatt regency Baltimore, 300 Light Street; Baltimore, MD- USA
It is the only event that delivers actionable strategies to help you respond to rapidly
evolving regulations, changing reimbursement paradigms, and the alliance management
scenarios unique to the diagnostics industry. Here you can build a solid infrastructure of
reliable partnerships and commercialization mechanisms, in order to put your research and
discovery technology to use in the most practical and profit table manner.
Contact: Matt Greenbaum; Tel: (888) 421-1442, 410.605.2846
E-mail: [email protected]
Dye+Chem
Jul 20-23, 2011
Bangabandhu International Conference Centre Dhaka, Bangladesh
It will be one of the biggest meeting places in Bangladesh for Buyers and
Suppliers of Dyes and Chemicals. It will also provide an interactive platform for
Exhibitors to generate business through displays/direct interaction and will
enhance the synergy effect and attract top level professionals from the Industry
thus improving technology, focus and visitors of the expo.
Conference and Exhibition Management services Limited House # 119,
Unit- A3, Road-1, Banani Block-F, Dhaka, Bangladesh.
Tel: +(880)-(2)-8812713; Fax: +(880)-(2)-9894573
Clinical Lab Expo
Jul 26-28, 2011
Georgia World Congress Center Atlanta, United States Of America
It is an international scientific/medical exposition of clinical laboratory
professionals, physicians, research scientists and other individuals involved with
clinical chemistry and other clinical laboratory science-related disciplines.
American Association For Clinical Chemistry1850-K Street, NW Suite 625,
Washington, United States Of America; Tel:+(1)-(800)-8921400
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
18
Pharma Professional
6.
Event
Date
Venue
Highlights
7.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
8.
Event
Date
Venue
Highlights
9.
Contact
Details
Event
Date
Venue
Highlights
10.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
July 2011
Materials for Medical Devices
Aug 08-10, 2011
Hilton Minneapolis Minneapolis, United States Of America
It is an annual event which brings together over 500 suppliers showcasing their
technology, knowledge and capabilities in the medical sciences field. This unique
expo witnesses ground breaking technology and innovations in the medical field. It
is one of the most highly regarded expo of medical equipments and draws in
widespread interest from scientific professionals.
ASM9639 Kinsman Road Materials Park, Ohio 44073-0002 USA, Tel:+(1)-(440)
338-5151
Intl. Petroleum & Petrochemical Technology and Equipment Exhibition
Aug 11-13, 2011
Canton Fair Pazhou Complex Area B Guangzhou, China
It will be the first fine and speciality chemicals exhibition to unite both domestic
and international exhibitors.
Guangzhou Grandeur Exhibition Service Co. Limited, 2/ F Meijing Garden,
No. 318 Chebei Road, Guangzhou, China
Tel:+(86)-(20)-28314758; Fax:+(86)-(20)-82579220
CPhi South America
Aug 24-26, 2011
Transamerica Expo Center Sao Paulo, Brazil
It will undoubtedly bring a wealth of opportunities to the pharmaceutical industry.
With a rapidly emerging market second only to China and a growth rate exceeding
that of the global average, South America continues to promote an attractive
business arena to many Western firms.
CMP InformationIndustrieweg 54, P.O. Box 200, 3600 AE, Maarsen, The
Netherlands; Tel:+(31)-(346)-559444; Fax: +(31)-(346)-573811
Pack Tech Asia
Aug 27-29, 2011
Milan Mela Ground Kolkata, India
It is an International Exhibition on processing, filling & packaging technology
which will showcase the entire spectrum of products, latest Trend, Technology
equipments and services in food processing, pharmaceuticals, beverages,
confectionery, bakery, Ayurveda and Herbal products, Cosmetics, Agro Products
and many more.
Kesari Media & Events Pvt. Ltd, Scf 172-A, First Floor, Grain Market Sector-26,
Chandigarh, India; Tel:+(91)-(172)-2790007
Pharma eMarketing Congress 2011
13-14 September 2011
Lisbon, Portugal
The Pharma eMarketing Congress reflects the dramatic marketing changes in the
Pharma industry that were prompted by technology changes in the past decade. It
helps to learn about Pharmaceutical eMarketing and brainstorm the best practices in
this booming Pharma sector.
PMR,ul. Dekerta 24, 30-703, Kraków, Poland; Tel. +48 12 618 90 00
Fax +48 12 618 90 08; E-mail: [email protected];
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
19
Pharma Professional
11.
Event
Date
Venue
Highlights
12.
Contact
Details
Event
Date
Venue
Highlights
13.
Contact
Details
Event
Date
Venue
Highlights
Contact
Details
14.
Event
Date
Venue
Highlights
Contact
Details
15.
Event
Date
Venue
Highlights
Contact
Details
July 2011
Pharmac India
Sep 17-19, 2011
Gujarat University Exhibition Hall
It is recognized as a focused exhibition for Pharma & Health care industry. It is 3
days exhibition which is aiming towards highlighting varied related medical
products. It will prove to be a large hub of reputed professionals from
pharmaceutical formulation, herbal products, veterinary drug, medical & disposal,
pharmaceutical machinery and many other sectors.
Orbitz Exhibitions Private Limited, 202, Navyug Industrial Estate, T. J. Road,
Sewree, Mumbai, India; Tel: +(91)-(22)-24102801; Fax: +(91)-(22)-24102805
Chemical Industry
Sep 26 – 01, Oct, 2011
International Fair Plovdiv Plovdiv, Bulgaria
The first edition of the exhibition was launched in 2004 based on the existing
Specialized Salon of Chemical Industry and in compliance with the modern trends
and developments in the exhibition industry. Our aim is to improve the
effectiveness of your participation.
International Fair Plovdiv, 37, Tzar Boris III - Obedinitel, Plovdiv, Bulgaria
Tel:+(359)-(32)-902000; Fax:+(359)-(32)-902432
India Chem Gujarat
Oct 13-15, 2011
Gujarat University Exhibition Hall Ahmedabad, Gujarat, India
It will showcase potential of the chemical and allied industry. The exhibition will
offer a platform for discussing varied areas of the sector along with the
environmental concerns. The event is being organized by Federation of Indian
Chambers of Commerce and Industry.
Federation of Indian Chambers of Commerce & Industry, Federation House, 1,
Tansen Marg, New Delhi - 110 001, India.
Tel: +(91)-(11)-23738760; Fax: +(91)-(11)-23320714
9th BioPharma India Convention 2011
Dec 6-8,2011
Mumbai, India
It is India’s only event where biopharma industry stakeholders across the entire
value chain gather. From partnering to drug discovery, manufacturing and clinical
trial, BioPharma India Convention brings you the latest developments in India that
allow you to be on top of your game.
Terrapinn Pte Ltd; 1 Harbourfront Place; #18-01 Harbourfront Tower 1; Singapore
098633; Tel: +65 6222 8550; Fax: +65 6226 3264
website: [email protected]
India Lab Expo
Dec 08-10, 2011
Pragati Maidan New Delhi, Delhi, India
It is the India's unique and most comprehensive exhibition on Laboratory,
Scientific, Biotechnology, Analytical, Educational, Material Testing, Diagnostics and
related products for major Indian and International manufacturers, exporters,
importers and key regional suppliers. This international trade exhibition focuses on
latest laboratory technologies and accessories. It is an ideal platform as a meeting
ground for scientists, researchers, and institutional heads and industry captains, to
look at viable laboratory solutions.
S. D. India Corporation, No. 595, 2nd Floor, Dr. Mukherjee Nagar,
New Delhi - 110 009, India.; Tel: +(91)-(11)-27604500; Fax: +(91)-(11)-27604600
A joint Initiative by IPA and Cygnus to enable Pharma Professionals to be more
successful
Indian Pharmaceutical Association
Kalina, Santacruz (E), Mumbai – 400 098.
Tel: 91-22-26671072; Fax: 91-22-26670744,
Email:[email protected]:: www.ipapharma.org
Cygnus Business Consulting & Research Pvt. Ltd
Plot No: 8-3-948/949, 1st Floor, Solitaire Plaza,
Behind Image Hospital, Ameerpet, Hyderabad- 500 073.
Tel: +91-40-23430203-07, Fax: +91-40-23430201,
Email: [email protected]; Website: www.cygnusindia.com
20